Skip to content

    Tarka

    Interactions

    Selected MAOIs/Selected Antihypertensive Agents

    This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

    Medical warning:

    Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

    How the interaction occurs:

    When these two medicines are taken together, the effects of one or both medicines may increase.

    What might happen:

    An increase in side effects of one or both medicines may occur. Using these medicines together may cause abnormally low blood pressure.

    What you should do about this interaction:

    If you experience dizziness, lightheadedness, or weakness, especially upon standing, contact your doctor. If you experience these symptoms, rise slowly when changing positions from lying to standing. The dose of your medicines may need adjusting. Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

    References:

    1.Nardil (phenelzine sulfate) US prescribing information. Parke-Davis May, 2007.

    2.Parnate (tranylcypromine sulfate) US prescribing information. GlaxoSmithKline May, 2010.

    3.Remick RA, Froese C. Monoamine oxidase inhibitors: clinical review. Can Fam Physician 1990 Jun;36:1151-5.

    4.Razani J, White KL, White J, Simpson G, Sloane RB, Rebal R, Palmer R. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 1983 Jun;40(6):657-61.

    5.Tulen JH, Volkers AC, van den Broek WW, Bruijn JA. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression. J Clin Psychopharmacol 2006 Oct; 26(5):542-4.

    Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, expect as may be authorized by the applicable terms of use.

    CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

    More about Drugs and Medications

    URAC Seal TRUSTe Privacy Certification TAG Registered Seal HONcode Seal AdChoices